About
This medication combines Dapagliflozin and Sitagliptin, offering a dual-mechanism approach for the treatment of type 2 diabetes mellitus. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and lower blood glucose levels, independent of insulin. Sitagliptin is a DPP-4 inhibitor that enhances the body's natural incretin system to improve glucose-dependent insulin secretion and suppress glucagon. This combination provides comprehensive glycemic control by addressing different pathophysiological aspects of type 2 diabetes, including insulin resistance, impaired insulin secretion, and increased hepatic glucose production. It is an effective option for patients seeking improved HbA1c levels and may offer additional benefits such as modest weight loss and blood pressure reduction.
Uses
- Management of type 2 diabetes mellitus.
- As an adjunct to diet and exercise.
- To improve glycemic control in adults.
- When monotherapy is insufficient.
Directions For Use
Take this combination tablet orally once daily in the morning, with or without food, as directed by your healthcare provider.
Benefits
- Provides significant reduction in HbA1c.
- Offers complementary mechanisms of action.
- May lead to modest weight loss (Dapagliflozin effect).
- Can reduce blood pressure (Dapagliflozin effect).
- Low risk of hypoglycemia when not combined with insulin/sulfonylureas.
- Potential cardiovascular and renal benefits (Dapagliflozin effect).
Side Effects
- Urinary tract infections
- Genital mycotic infections
- Nasopharyngitis
- Headache
- Diarrhea
- Nausea
- Increased urination
- Back pain
- Joint pain
- Dizziness
- Hypotension (especially in susceptible patients)
- Ketoacidosis (rare, SGLT2 inhibitor-related)
Safety Measures
- Alcohol - Excessive alcohol intake can increase the risk of dehydration and ketoacidosis, especially with SGLT2 inhibitors. Limit consumption.
- Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential renal effects on the fetus. Consult a doctor.
- Breastfeeding - It is unknown if these drugs are excreted in human milk. Avoid use during breastfeeding or consult a healthcare provider.
- Liver - No dose adjustment typically required for mild to moderate hepatic impairment. Use with caution in severe impairment.
- Kidney - Dapagliflozin is not recommended for patients with eGFR <25 mL/min/1.73m². Sitagliptin requires dose adjustment in renal impairment.
- Lung - No specific contraindications related to lung conditions.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!